rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2017-429-435rsp-2417Research ArticleОБЗОРREVIEWПоражение печени при псориазе и псориатическом артрите: обзор литературыLIVER DAMAGE IN PSORIASIS AND PSORIATIC ARTHRITIS: A LITERATURE REVIEWКорсаковаЮ. Л.KorsakovaYu. L.

115522 Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

yulkorsakova@bk.ruКоротаеваТ. В.KorotaevaT. V.

115522 Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation201729092017554429435Copyright © Корсакова Ю.Л., Коротаева Т.В., 20172017Корсакова Ю.Л., Коротаева Т.В.Korsakova Y.L., Korotaeva T.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2417

Псориаз (Пс) является хроническим системным заболеванием, поражающим кожу. Исследования позволили выявить высокую распространенность неалкогольной жировой болезни печени (НАЖБП) у больных Пс по сравнению с общей популяцией, особенно у тех, кто страдает среднетяжелыми и тяжелыми формами Пс с высоким индексом распространенности и тяжести Пс (PASI). Определенную роль в этой взаимосвязи играют аналогичные патогенетические процессы. Среди наиболее вероятных причин выделяют резистентность к инсулину и повышение уровней провоспалительных цитокинов. По последним данным, распространенность НАЖБП и метаболического синдрома среди больных Пс выше, чем в популяции в целом. Кроме того, пациенты с НАЖБП и Пс имеют более высокий риск развития тяжелого фиброза печени, чем лица с НАЖБП и без Пс. Терапия этого состояния несомненно должна проводиться по пути не только модификации традиционных факторов риска, но и надежного подавления воспаления. Наличие ожирения и НАЖБП оказывает отрицательное влияние и на результаты лечения больных псориатическим артритом генно-инженерными биологическими препаратами.

Psoriasis (Ps) is a chronic systemic disease that affects the skin. Investigation could reveal the high prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with Ps compared with the general population, especially in those who have moderate to severe Ps with a high Ps area severity index (PASI). Similar pathogenic processes play a definite role in this relationship. The most likely causes are recognized to be insulin resistance and elevated levels of proinflammatory cytokines. According to recent evidence, the prevalence of NAFLD and metabolic syndrome in patients with Ps is higher than that in the general population. In addition, patients with NAFLD and Ps are at higher risk of severe liver fibrosis than those with NAFLD without Ps. Therapy for this condition certainly needs not only to modify traditional risk factors, but also to reliably suppress inflammation. Obesity and NAFLD have a negative impact on the results of treatment in patients with psoriatic arthritis with biological agents.

псориазпсориатический артритнеалкогольная жировая болезнь печениpsoriasispsoriatic arthritisnonalcoholic fatty liver diseaseReferencesDavidovici BB, Sattar N, Prinz JC, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130:1785-96. doi: 10.1038/jid.2010.103Davidovici BB, Sattar N, Prinz JC, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130:1785-96. doi: 10.1038/jid.2010.103Christophers E. Psoriasis – epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26:314-20. doi: 10.1046/j.1365-2230.2001.00832.xChristophers E. Psoriasis – epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26:314-20. doi: 10.1046/j.1365-2230.2001.00832.xSchon MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352:1899-912. doi: 10.1056/NEJMra041320Schon MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352:1899-912. doi: 10.1056/NEJMra041320Ganzetti G, Campanati A, Scocco V, et al. The potential effect of the tumour necrosis factor-α inhibitors on vitamin D status in psoriatic patients. Acta Derm Venereol. 2014;94:715-7. doi: 10.2340/00015555-1801Ganzetti G, Campanati A, Scocco V, et al. The potential effect of the tumour necrosis factor-α inhibitors on vitamin D status in psoriatic patients. Acta Derm Venereol. 2014;94:715-7. doi: 10.2340/00015555-1801Naldi L, Gambini D. The clinical spectrum of psoriasis. Clin Dermatol. 2007;25:510-8. doi: 10.1016/j.clindermatol. 2007.08.003Naldi L, Gambini D. The clinical spectrum of psoriasis. Clin Dermatol. 2007;25:510-8. doi: 10.1016/j.clindermatol. 2007.08.003Koo J, Lee E, Lee CS, et al. Psoriasis. J Am Acad Dermatol. 2004;50:4. doi: 10.1016/j.jaad.2003.11.046Koo J, Lee E, Lee CS, et al. Psoriasis. J Am Acad Dermatol. 2004;50:4. doi: 10.1016/j.jaad.2003.11.046Rivera R, Vanaclocha F. Nonalcoholic fatty liver disease and psoriasis. Actas Dermosifiliogr. 2010;101:657-8. doi: 10.1016/j.ad.2010.06.004Rivera R, Vanaclocha F. Nonalcoholic fatty liver disease and psoriasis. Actas Dermosifiliogr. 2010;101:657-8. doi: 10.1016/j.ad.2010.06.004Farley E, Menter A. Psoriasis: comorbidities and associations. Ital Dermatol Venereol. 2011;146:9-15.Farley E, Menter A. Psoriasis: comorbidities and associations. Ital Dermatol Venereol. 2011;146:9-15.Ramos AN, de Oliveira Rocha B, de Almeida Rego V, et al. The linkage between psoriasis and non-alcoholic fatty liver disease: a literature review. Acta Dermatovenerol Croat. 2014;22(2):132-6.Ramos AN, de Oliveira Rocha B, de Almeida Rego V, et al. The linkage between psoriasis and non-alcoholic fatty liver disease: a literature review. Acta Dermatovenerol Croat. 2014;22(2):132-6.Boehncke WH, Boehncke S. More than skin-deep: the many dimensions of the psoriatic disease. Swiss Med Wkly. 2014;144:w13968. doi: 10.4414/smw.2014.13968Boehncke WH, Boehncke S. More than skin-deep: the many dimensions of the psoriatic disease. Swiss Med Wkly. 2014;144:w13968. doi: 10.4414/smw.2014.13968Gisondi P, Targher G, Zoppini G, et al. Non-alcoholic fatty liver disease in patients with chronic plaques psoriasis. J Hepatol. 2009;51:758-64. doi: 10.1016/j.jhep.2009.04.020Gisondi P, Targher G, Zoppini G, et al. Non-alcoholic fatty liver disease in patients with chronic plaques psoriasis. J Hepatol. 2009;51:758-64. doi: 10.1016/j.jhep.2009.04.020Torres T, Bettencourt N. Psoriasis: the visible killer. Rev Port Cardiol. 2014;33:95-9. doi: 10.1016/j.repc.2013.06.017Torres T, Bettencourt N. Psoriasis: the visible killer. Rev Port Cardiol. 2014;33:95-9. doi: 10.1016/j.repc.2013.06.017Onumah N, Kircik LH. Psoriasis and its comorbidities. J Drugs Dermatol. 2012;11:s5-10.Onumah N, Kircik LH. Psoriasis and its comorbidities. J Drugs Dermatol. 2012;11:s5-10.Paschos P, Paleta K. Nonalcoholic fatty liver disease and metabolic syndrome. Hippokratia. 2009;13:9-19.Paschos P, Paleta K. Nonalcoholic fatty liver disease and metabolic syndrome. Hippokratia. 2009;13:9-19.Gisondi P, Ferrazzi A, Girolomoni G. Metabolic comorbidities and psoriasis. Acta Dermatovenerol Croat. 2010;18:297-304.Gisondi P, Ferrazzi A, Girolomoni G. Metabolic comorbidities and psoriasis. Acta Dermatovenerol Croat. 2010;18:297-304.Ludwig J, Viqgiano TR, McGill DB, et al. Nonalcoholic statohepatitis: Meyo Clinic experience with a hitherto unnamed disease. Meyo Clin Proc. 1980;55:434-8.Ludwig J, Viqgiano TR, McGill DB, et al. Nonalcoholic statohepatitis: Meyo Clinic experience with a hitherto unnamed disease. Meyo Clin Proc. 1980;55:434-8.Farrel GC, Larter CZ. Non-alcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology. 2006;43:S99-S112. doi: 10.1002/hep.20973Farrel GC, Larter CZ. Non-alcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology. 2006;43:S99-S112. doi: 10.1002/hep.20973Полунина ТЕ, Маев ИВ. Неалкогольная жировая болезнь печени: эпидемиология, патогенез, диагностика, лечение. Consilium medicum. Гастроэнтерология. 2012;(1):35-40 [Polunina TE, Maev IV. Non-alcoholic fatty liver disease: epidemiology, pathogenesis, diagnosis, treatment. Consilium Medicum. Gastroenterologiya. 2012;(1):35-40 (In Russ.)].Полунина ТЕ, Маев ИВ. Неалкогольная жировая болезнь печени: эпидемиология, патогенез, диагностика, лечение. Consilium medicum. Гастроэнтерология. 2012;(1):35-40 [Polunina TE, Maev IV. Non-alcoholic fatty liver disease: epidemiology, pathogenesis, diagnosis, treatment. Consilium Medicum. Gastroenterologiya. 2012;(1):35-40 (In Russ.)].Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372-84. doi: 10.1016/j.jhep.2010.04.008Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372-84. doi: 10.1016/j.jhep.2010.04.008European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO). EASLEASD- EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388-402. doi: 10.1016/j.jhep.2015.11.004European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO). EASLEASD- EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388-402. doi: 10.1016/j.jhep.2015.11.004Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med. 2005;22:1129-33. doi: 10.1111/j.1464-5491.2005.01748.xAdams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med. 2005;22:1129-33. doi: 10.1111/j.1464-5491.2005.01748.xBitencourt AGV, Cotrim HP, Alves E, et al. Doenca hepatica gordurosa nao alcoolica: caracteristicas clinicas e histologicas em obesos graves submetidos a cirurgia bariatrica. Acta Gastroenterol Latinoam. 2007;37:224-30.Bitencourt AGV, Cotrim HP, Alves E, et al. Doenca hepatica gordurosa nao alcoolica: caracteristicas clinicas e histologicas em obesos graves submetidos a cirurgia bariatrica. Acta Gastroenterol Latinoam. 2007;37:224-30.Kotronen A, Yki-Jä rvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28:27-38. doi: 10.1161/ATVBAHA.107.147538Kotronen A, Yki-Jä rvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28:27-38. doi: 10.1161/ATVBAHA.107.147538Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-95. doi: 10.1002/hep.20466Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-95. doi: 10.1002/hep.20466Karnikowiski M, Cordova C, Oliveira RJ, et al. Non-alcoholic fatty liver disease and metabolic syndrome in Brazilian medianaged and older adults. Sao Paulo Med J. 2007;125:333-7. doi: 10.1590/S1516-31802007000600006Karnikowiski M, Cordova C, Oliveira RJ, et al. Non-alcoholic fatty liver disease and metabolic syndrome in Brazilian medianaged and older adults. Sao Paulo Med J. 2007;125:333-7. doi: 10.1590/S1516-31802007000600006Anstee QM, Daly AK, Day CP. Genetics of alcoholic and nonalcoholic fatty liver disease. Semin Liver Dis. 2011;31:128-46. doi: 10.1055/s-0031-1276643Anstee QM, Daly AK, Day CP. Genetics of alcoholic and nonalcoholic fatty liver disease. Semin Liver Dis. 2011;31:128-46. doi: 10.1055/s-0031-1276643Leonardo A, Loria P, Carulli N. Concurrent non-alcoholic steatohepatitis and psoriasis. Report of three cases from the POLI. ST.E.N.A. study. Dig Liver Dis. 2001;33:86-7 [PMID: 11303985].Leonardo A, Loria P, Carulli N. Concurrent non-alcoholic steatohepatitis and psoriasis. Report of three cases from the POLI. ST.E.N.A. study. Dig Liver Dis. 2001;33:86-7 [PMID: 11303985].Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846-54. doi: 10.1002/hep.21496Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846-54. doi: 10.1002/hep.21496Vanni E, Bugianesi E, Kotronen A, et al. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis. 2010;42:320-30. doi: 10.1016/j.dld.2010.01.016Vanni E, Bugianesi E, Kotronen A, et al. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis. 2010;42:320-30. doi: 10.1016/j.dld.2010.01.016Mantovani A, Gisondi P, Lonardo A, et al. Relationship between non-alcoholic fatty liver disease and psoriasis: A novel hepatodermal axis? Int J Mol Sci. 2016;17:217. doi: 10.3390/ijms17020217Mantovani A, Gisondi P, Lonardo A, et al. Relationship between non-alcoholic fatty liver disease and psoriasis: A novel hepatodermal axis? Int J Mol Sci. 2016;17:217. doi: 10.3390/ijms17020217Miele L, Vallone S, Cefalo C, et al. Prevalence, characteristics and severity of non- alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51:778-86. doi: 10.1016/j.jhep.2009.06.008Miele L, Vallone S, Cefalo C, et al. Prevalence, characteristics and severity of non- alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51:778-86. doi: 10.1016/j.jhep.2009.06.008Madanagobalane S, Anandan S. The increased prevalence of nonalcoholic fatty liver disease in psoriaticpatients: A study from South India. Australas J Dermatol. 2012;53:190-7. doi: 10.1111/j.1440-0960.2012.00905.xMadanagobalane S, Anandan S. The increased prevalence of nonalcoholic fatty liver disease in psoriaticpatients: A study from South India. Australas J Dermatol. 2012;53:190-7. doi: 10.1111/j.1440-0960.2012.00905.xVan der Voort EA, Koehler EM, Dowlatshahi EA, et al. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study. J Am Acad Dermatol. 2014;70:517-24. doi: 10.1016/j.jaad.2013.10.044Van der Voort EA, Koehler EM, Dowlatshahi EA, et al. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study. J Am Acad Dermatol. 2014;70:517-24. doi: 10.1016/j.jaad.2013.10.044Van der Voort EA, Koehler EM, Nijsten T, et al. Increased prevalence of advanced liver fibrosis in patients with psoriasis: A crosssectional analysis from the Rotterdam study. Acta Derm Venereol. 2016;96:213-7. doi: 10.2340/00015555-2161Van der Voort EA, Koehler EM, Nijsten T, et al. Increased prevalence of advanced liver fibrosis in patients with psoriasis: A crosssectional analysis from the Rotterdam study. Acta Derm Venereol. 2016;96:213-7. doi: 10.2340/00015555-2161Gisondi P, Barba E, Girolomoni G. Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis. J Eur Acad Dermatol Venereol. 2015;30:282-7. doi: 10.1111/jdv.13456Gisondi P, Barba E, Girolomoni G. Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis. J Eur Acad Dermatol Venereol. 2015;30:282-7. doi: 10.1111/jdv.13456Abedini R, Salehi M, Lajevardi V, et al. Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease. Clin Exp Dermatol. 2015;40:722-7. doi: 10.1111/ced.12672Abedini R, Salehi M, Lajevardi V, et al. Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease. Clin Exp Dermatol. 2015;40:722-7. doi: 10.1111/ced.12672Roberts KK, Cochet AE, Lamb PB, et al. The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic. Aliment Pharmacol Ther. 2015;41:293-300. doi: 10.1111/apt.13042Roberts KK, Cochet AE, Lamb PB, et al. The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic. Aliment Pharmacol Ther. 2015;41:293-300. doi: 10.1111/apt.13042Candia R, Ruiz A, Torres-Robles R, et al. Risk of non-alcoholic fatty liver disease in patients with psoriasis: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2015;29:656-62. doi: 10.1111/jdv.12847Candia R, Ruiz A, Torres-Robles R, et al. Risk of non-alcoholic fatty liver disease in patients with psoriasis: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2015;29:656-62. doi: 10.1111/jdv.12847Das UN. Is obesity an inflammatory condition? Nutrition. 2001;17:953-66. doi: 10.1016/S0899-9007(01)00672-4Das UN. Is obesity an inflammatory condition? Nutrition. 2001;17:953-66. doi: 10.1016/S0899-9007(01)00672-4Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548-56. doi: 10.1210/jc.2004-0395Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548-56. doi: 10.1210/jc.2004-0395Campanati A, Ganzetti G, Marra M, et al. Serum levels of adipocytokines in psoriatic patients receiving TNF-alpha inhibitors: results of a retrospective analysis. Intern J Dermatol. 2015;54:839-45. doi: 10.1111/ijd.12706Campanati A, Ganzetti G, Marra M, et al. Serum levels of adipocytokines in psoriatic patients receiving TNF-alpha inhibitors: results of a retrospective analysis. Intern J Dermatol. 2015;54:839-45. doi: 10.1111/ijd.12706Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxford). 2006;64:355-65. doi: 10.1111/j.1365-2265.2006.02474.xRonti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxford). 2006;64:355-65. doi: 10.1111/j.1365-2265.2006.02474.xOuchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta. 2007;380:24-30. doi: 10.1016/j.cca.2007.01.026Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta. 2007;380:24-30. doi: 10.1016/j.cca.2007.01.026Xu A, Wang Y, Keshaw H, et al. The fatderived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003;112:91-100. doi: 10.1172/JCI200317797Xu A, Wang Y, Keshaw H, et al. The fatderived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003;112:91-100. doi: 10.1172/JCI200317797Masaki T, Chiba S, Tatsukawa H, et al. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology. 2004;40:177-84. doi: 10.1002/hep.20282Masaki T, Chiba S, Tatsukawa H, et al. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology. 2004;40:177-84. doi: 10.1002/hep.20282Polyzos SA, Toulis KA, Goulis DG, et al. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and metaanalysis. Metabolism. 2011;60:313-26. doi: 10.1016/j.metabol.2010.09.003Polyzos SA, Toulis KA, Goulis DG, et al. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and metaanalysis. Metabolism. 2011;60:313-26. doi: 10.1016/j.metabol.2010.09.003Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116:1784-92. doi: 10.1172/JCI29126Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116:1784-92. doi: 10.1172/JCI29126Targher G, Bertolini L, Scala L, et al. Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. Clin Endocrinol (Oxford). 2004;61:700-3. doi: 10.1111/j.1365-2265.2004.02151.xTargher G, Bertolini L, Scala L, et al. Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. Clin Endocrinol (Oxford). 2004;61:700-3. doi: 10.1111/j.1365-2265.2004.02151.xCoates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheum. 2016 May;68(5):1060-71. doi: 10.1002/art.39573Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheum. 2016 May;68(5):1060-71. doi: 10.1002/art.39573Vilarrasa E, Puig L, Alomar A. Biologic treatments for psoriasis in patients with hepatitis C virus infection and other liver diseases: experience in 29 patients. JEADV. 2010;24:P013.Vilarrasa E, Puig L, Alomar A. Biologic treatments for psoriasis in patients with hepatitis C virus infection and other liver diseases: experience in 29 patients. JEADV. 2010;24:P013.Schramm C, Schneider A, Marx A, et al. Adalimumab could suppress the activity of non alcoholic steatohepatitis (NASH). Z Gastroenterol. 2008;46:1369-71. doi: 10.1055/s-2008-1027411Schramm C, Schneider A, Marx A, et al. Adalimumab could suppress the activity of non alcoholic steatohepatitis (NASH). Z Gastroenterol. 2008;46:1369-71. doi: 10.1055/s-2008-1027411Bhutani T, Hong J, Koo J. Contemporary diagnosis and management of psoriasis. 5th ed. Newtown, PA: Handbooks in Healthcare; 2011. P. 50-9.Bhutani T, Hong J, Koo J. Contemporary diagnosis and management of psoriasis. 5th ed. Newtown, PA: Handbooks in Healthcare; 2011. P. 50-9.Toussirot E, Aubin F, Dumoulin G. Relationships between adipose tissue and psoriasis, with or without arthritis. Front Immunol. 2014;5:368. doi: 10.3389/fimmu.2014.00368Toussirot E, Aubin F, Dumoulin G. Relationships between adipose tissue and psoriasis, with or without arthritis. Front Immunol. 2014;5:368. doi: 10.3389/fimmu.2014.00368Di Minno MND, Peluso R, Iervolino S, et al. Hepatic steatosis, carotid plaques and achieving MDA in psoriatic arthritis patients starting TNF-α blockers treatment: a prospective study. Arthritis Res Ther. 2012;14(5):R211. doi: 10.1186/ar4049Di Minno MND, Peluso R, Iervolino S, et al. Hepatic steatosis, carotid plaques and achieving MDA in psoriatic arthritis patients starting TNF-α blockers treatment: a prospective study. Arthritis Res Ther. 2012;14(5):R211. doi: 10.1186/ar4049Di Minno MND, Peluso R, Iervolino S, et al. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Ann Rheum Dis. 2014;73:1157-62. doi: 10.1136/annrheumdis-2012-202812Di Minno MND, Peluso R, Iervolino S, et al. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Ann Rheum Dis. 2014;73:1157-62. doi: 10.1136/annrheumdis-2012-202812Di Minno MND, Peluso R, Iervolino S, et al. Obesity and the prediction of minimal disease. Arthritis Care Res. 2013;65(1):141-7. doi: 10.1002/acr.21711Di Minno MND, Peluso R, Iervolino S, et al. Obesity and the prediction of minimal disease. Arthritis Care Res. 2013;65(1):141-7. doi: 10.1002/acr.21711Hojgaard P, Glintborg B, Kristensen LE, et al. The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. Rheumatology (Oxford). 2016 Dec;55(12):2191-9. doi: 10.1093/rheumatology/kew326Hojgaard P, Glintborg B, Kristensen LE, et al. The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. Rheumatology (Oxford). 2016 Dec;55(12):2191-9. doi: 10.1093/rheumatology/kew326

The authors declare that there are no conflicts of interest present.